Enzymotec secures new funding

- Last updated on GMT

Related tags: Finance

Israeli phospholipids specialist, Enzymotec, has raised $11 million (€8.54m) from its three major shareholders as well as a new investor – Arancia International, a privately owned Mexican ingredients developer with expertise in biotechnology and enzymes.

"We are excited to join Enzymotec and be a part of the development and production of lipid-based innovative health solutions,"​ said Arancia executive president, Luis Aranguren.

Enzymotec is in the process of finalising a further $7m (€5.44m) from a major Israeli bank.

“The successful completion of the financial round validates the strength and potential of Enzymotec, particularly given current economic conditions,"​ said Enzymotec president and CEO, Dr Ariel Katz.

He said the funding would allow completion of a new facility in Israel and back ongoing research and development.

Enzymotec’s existing shareholders are Galam Ltd, Ofer Hi-Tech Investments Ltd and Millennium II Materials Technology Fund L.P.

Related news

Show more

Related products

show more

Attract a new generation of omega-3 consumers

Attract a new generation of omega-3 consumers

DSM Nutritional Products | 15-Sep-2022 | Infographic

Want to bring your next omega-3 innovation to market quickly and sustainably? DSM's algal-sourced life's™OMEGA, enables you to get consumer-driven,...

DurOmega® Algal DHA 20% water dispersible powder

DurOmega® Algal DHA 20% water dispersible powder

INNOBIO Corporation Limited | 30-May-2022 | Technical / White Paper

INNOBIO most recently launched a new product DurOmega® Algal DHA 20% water dispersible powder with significantly reduced fishy odor and taste, which optimizes...

Related suppliers

Follow us

Products

View more

Webinars